avacincaptad pegol
{{Short description|Medication}}
{{Use American English|date=August 2023}}
{{Use dmy dates|date=August 2023}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Infobox drug
| image =
| width =
| alt =
| caption =
| pronounce =
| tradename = Izervay
| Drugs.com =
| MedlinePlus =
| DailyMedID = Avacincaptad pegol
| pregnancy_AU =
| pregnancy_AU_comment =
| pregnancy_category =
| routes_of_administration = Intravitreal
| class = Complement inhibitor
| ATC_prefix = S01
| ATC_suffix = XA32
| ATC_supplemental =
| legal_AU =
| legal_AU_comment =
| legal_BR =
| legal_BR_comment =
| legal_CA =
| legal_CA_comment =
| legal_DE =
| legal_DE_comment =
| legal_NZ =
| legal_NZ_comment =
| legal_UK =
| legal_UK_comment =
| legal_US = Rx-only
| legal_EU =
| legal_EU_comment =
| legal_UN =
| legal_UN_comment =
| legal_status =
| bioavailability =
| protein_bound =
| metabolism =
| metabolites =
| onset =
| elimination_half-life =
| duration_of_action =
| excretion =
| CAS_number = 1613641-69-2
| CAS_supplemental =
| PubChem =
| IUPHAR_ligand =
| DrugBank = DB15165
| ChemSpiderID =
| UNII = TT0V5JLG5B
| KEGG = D11748
| ChEBI =
| ChEMBL =
| NIAID_ChemDB =
| PDB_ligand =
| synonyms = Zimura
| IUPAC_name =
| chemical_formula_ref =
| chemical_formula =
| C=395|H=453|F=21|N=142|Na=39|O=262|P=39 | charge=
| molecular_weight =
| molecular_weight_comment =
| SMILES =
| StdInChI =
| StdInChI_comment =
| StdInChIKey =
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}}
Avacincaptad pegol, sold under the brand name Izervay, is a medication used for the treatment of age-related macular degeneration. Avacincaptad pegol is a complement inhibitor.
Avacincaptad pegol was approved for medical use in the United States in August 2023.{{cite web | title=Novel Drug Approvals for 2023 | website=U.S. Food and Drug Administration (FDA) | date=18 August 2023 | url=https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2023 | access-date=25 August 2023 | archive-date=21 January 2023 | archive-url=https://web.archive.org/web/20230121035617/https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2023 | url-status=live }} {{PD-notice}}{{cite press release | title=Iveric Bio Receives U.S. FDA Approval for Izervay (avacincaptad pegol intravitreal solution), a New Treatment for Geographic Atrophy | publisher=Astellas Pharma Inc. | via=PR Newswire | date=4 August 2023 | url=https://www.prnewswire.com/news-releases/iveric-bio-receives-us-fda-approval-for-izervay-avacincaptad-pegol-intravitreal-solution-a-new-treatment-for-geographic-atrophy-301894042.html | access-date=25 August 2023 | archive-date=26 August 2023 | archive-url=https://web.archive.org/web/20230826063111/https://www.prnewswire.com/news-releases/iveric-bio-receives-us-fda-approval-for-izervay-avacincaptad-pegol-intravitreal-solution-a-new-treatment-for-geographic-atrophy-301894042.html | url-status=live }}{{cite journal | vauthors = Kang C | title = Avacincaptad Pegol: First Approval | journal = Drugs | volume = 83 | issue = 15 | pages = 1447–1453 | date = October 2023 | pmid = 37814173 | doi = 10.1007/s40265-023-01948-8 | s2cid = 263801918 | url = https://figshare.com/articles/online_resource/Avacincaptad_Pegol_First_Approval/24123651 | access-date = 18 December 2023 | archive-date = 27 April 2024 | archive-url = https://web.archive.org/web/20240427134435/https://figshare.com/articles/online_resource/Avacincaptad_Pegol_First_Approval/24123651 | url-status = live }}
Medical uses
Avacincaptad pegol is indicated for the treatment of geographic atrophy secondary to age-related macular degeneration.{{cite web | title=Drug Approval Package: Izervay | website=U.S. Food and Drug Administration (FDA) | date=1 September 2023 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217225Orig1s000TOC.cfm | access-date=20 November 2023 | archive-date=20 November 2023 | archive-url=https://web.archive.org/web/20231120061523/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/217225Orig1s000TOC.cfm | url-status=live }}
Society and culture
Avacincaptad pegol is the international nonproprietary name.{{cite journal | vauthors = ((World Health Organization)) | title=International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 75 | journal=WHO Drug Information | volume=30 | issue=1 | year=2016 | hdl=10665/331046 | hdl-access=free | author-link = World Health Organization }}
References
{{reflist}}
External links
- {{ClinicalTrialsGov|NCT02686658|Zimura in Participants With Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration}}
- {{ClinicalTrialsGov|NCT04435366|A Phase 3 Safety and Efficacy Study of Intravitreal Administration of Zimura (Complement C5 Inhibitor)}}
{{Portal bar | Medicine}}
{{Pharma-stub}}